Skip to content

Fermented Millet Porridge, Gut Microbiota and Inflammation Status in Women

Effect of Fermented Millet Porridge on Gut Microbiota Diversity and Inflammation Markers in Women of Reproductive Age in Rural Burkina Faso: A Pilot Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05299970
Acronym
LAFIABAGA
Enrollment
80
Registered
2022-03-29
Start date
2022-03-21
Completion date
2024-07-31
Last updated
2023-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Microbiome, Human

Brief summary

Maternal undernutrition concerns 10-19% of women of reproductive age globally, the vast majority of which live in sub Saharan Africa and south Asia. Recommendations for nutritional interventions to tackle the problem range from per-pregnancy supplementation to upstream interventions targeting women of reproductive age before conception. To render the latter interventions cost-effective and sustainable, experts recommend to focus on food processing that leads to an enhanced nutrient content. One such method, which has been known and practiced for centuries in diverse societies, is fermentation. Traditionally fermented foods are diverse, widespread and highly appreciated in Burkina Faso. The present study aims to investigate the effect of fermented millet porridge on gut microbiota diversity, stool short chain fatty acid concentration and inflammation markers level in women of reproductive age living in rural Burkina Faso.

Interventions

A millet porridge (fermented or not, depending on group allocation) serving will be provided to participants daily, for consumption. consumption will be directly observed.

Sponsors

University Ghent
CollaboratorOTHER
Bill and Melinda Gates Foundation
CollaboratorOTHER
Institut de Recherche en Sciences de la Sante, Burkina Faso
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

Participant are * 18 to 49 years old * Resident in the study area and do not plan to move within 5 months following the start of the study * Are not on antibiotic treatment on inclusion and have not been in the previous 3 weeks. * Do not suffer from any pathology that could interfere with their diet. * Have no known allergy to pearl millet or its derivatives * Agree to sign a consent to participate in the study-

Exclusion criteria

* Women under 18 or over 49 * Women not consuming pearl millet porridge due to allergy or food preference * Women planning to move from the study area within 5 months of the start of the study * Women with serious illnesses that may interfere with their diet * Women on antibiotic treatment or at the time of inclusion or having been in the previous 3 weeks. * In addition, women who will benefit from antibiotic therapy during the study will be excluded from the analysis

Design outcomes

Primary

MeasureTime frameDescription
Gut microbiota diversity0 to 13 weeksgut microbiota alpha and beta diversity
Concentration of inflammation markers in blood and stool0 to 13 weeksConcentration of IL1-beta, IL 8, IL 6, IL 33, TNF-alpha, lipocalin 2, myeloperoxidase, calprotectin

Secondary

MeasureTime frameDescription
relative abundance of bacterial and fugal micro-organisms in millet dough and porridge2 to 8 weeksCount of microbial populations
Concentration of short chain fatty acid in stool0 to 13 weeksConcentration of C2-C8 fatty acids in stool
Number of participant with anemia0 to 13 weekshemoglobin concentration in grams per deciliter
Concentration of Ferritin in plasma0- to 13 weeksFerritin levels in Plasma
concentration of macronutrients in millet dough and porridge2 to 8 weeksLevels of carbohydrates, lipids, protein, dietary fiber and phytates

Countries

Burkina Faso

Contacts

Primary ContactLaeticia C TOE, MD
cellaety@yahoo.fr0022671007272
Backup ContactLionel O Ouedraogo
lionel.olivier.ouedraogo@gmail.com0022670530583

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026